Collegium Pharmaceutical, INC

Collegium Pharmaceutical, Inc. has finalized its acquisition of AZSTARYS from Corium Therapeutics Holdings, LLC for approximately $655.6 million, expanding its central nervous system drug offerings.

Collegium Pharmaceutical shareholders re-elected eight directors and ratified executive compensation and auditors at the 2026 Annual Meeting.

Collegium Pharmaceutical has finalized its acquisition of AZSTARYS, a CNS stimulant for ADHD, and has increased its 2026 financial outlook.

Collegium Pharmaceutical announced strong first quarter 2026 financial results, with net revenues up 9% year-over-year, driven by significant growth in JORNAY PM and its pain portfolio, while advancing its planned acquisition of AZSTARYS.

Collegium Pharmaceutical announced board changes including the nomination of Michael Donovan and the retirement of Dr. John Fallon.

Collegium Pharmaceutical will acquire AZSTARYS for $650 million in cash, strengthening its ADHD market position and accelerating growth.

Collegium Pharmaceutical reported a 9% increase in Q1 2026 revenue to $193.5 million, driven by strong performance in Jornay PM and Xtampza ER, while nearing the completion of its AZSTARYS acquisition.

Collegium Pharmaceutical, Inc. reported a significant increase in net income and product revenues for the third quarter of 2025, driven primarily by strong performance of Jornay PM following its acquisition.

Collegium Pharmaceutical reports a significant drop in net income for Q2 2025 despite revenue growth, driven by increased operating expenses and amortization from its Ironshore acquisition.

Collegium Pharmaceutical reports increased revenue in Q1 2025 driven by recent acquisition and product performance, while managing integration and ongoing litigation.

Collegium Pharmaceutical's Q3 2024 results show increased revenue driven by recent acquisition, but also increased expenses and a net income decrease compared to the same period last year.

Collegium Pharmaceutical's Q2 2024 results show a slight revenue increase and a net income of $19.6 million, alongside strategic moves including a new acquisition and debt refinancing.

Collegium Pharmaceutical, Inc. announced a significant increase in net product revenues for 2025, primarily fueled by the full-year contribution of Jornay PM and strategic acquisitions.

Collegium Pharmaceutical's 2024 results show revenue growth driven by the acquisition of Ironshore and increased sales of Belbuca and Xtampza ER, despite declines in Nucynta Products revenue.

Collegium Pharmaceutical details its stock incentive plan and reports its 2023 annual financial results, highlighting revenue growth and strategic shifts.

Gino Santini, a Director at Collegium Pharmaceutical, Inc., reported the acquisition of 8,700 shares of common stock through the exercise of a stock option.

Director Nancy Lurker of Collegium Pharmaceutical, Inc. acquired 8,741 shares of common stock through the grant of restricted stock units.

Carlos V. Paya, a Director at Collegium Pharmaceutical, Inc., acquired 8,741 shares of common stock through a grant of restricted stock units.

John Gordon Freund, a Director at Collegium Pharmaceutical, Inc., reported transactions involving restricted stock units (RSUs) and stock options.

Director Nancy Lurker sold 4,500 shares of Collegium Pharmaceutical, Inc. common stock at a weighted average price of $35.9691.

David Dieter, EVP & General Counsel of Collegium Pharmaceutical, Inc., reported a transaction involving the sale of 8,840 shares of common stock.

Collegium Pharmaceutical, Inc. has issued its proxy statement for the 2026 Annual Meeting of Shareholders, detailing director nominations, executive compensation, and accounting firm ratification.

Collegium Pharmaceutical will hold its annual shareholder meeting virtually on May 15, 2025, to vote on director elections, executive compensation, and other proposals.

Collegium Pharmaceutical's proxy statement highlights a transformational year in 2024, marked by strategic acquisitions, financial achievements, and a forward-looking approach to growth and shareholder value.

Collegium Pharmaceutical announces the withdrawal of Joseph Ciaffoni as a director nominee due to his upcoming departure as CEO, leading to a reduction in the board size.

Collegium Pharmaceutical will hold its annual shareholder meeting virtually on May 16, 2024, to vote on director elections, executive compensation, and auditor ratification.

Collegium Pharmaceutical achieved record net product revenue and adjusted EBITDA in 2023, increased its cash position, and executed its capital deployment strategy, including share repurchases.

Vanguard Capital Management has reported beneficial ownership of 5.01% of Collegium Pharmaceutical Inc.'s common stock as of June 30, 2026.

Janus Henderson Group plc has reported beneficial ownership of 5.8% of Collegium Pharmaceutical, Inc. common stock as of March 31, 2026.

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has filed a Schedule 13G, reporting beneficial ownership of 4.5% of Collegium Pharmaceutical, Inc. common stock as of March 31, 2026.

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a beneficial ownership of 4.53% in Collegium Pharmaceutical, Inc.

Millennium Management and affiliated entities have disclosed a reduction in their beneficial ownership of Collegium Pharmaceutical, Inc. to below the 5% reporting threshold.

Invesco Ltd. has filed a Schedule 13G reporting a 5.0% beneficial ownership stake in Collegium Pharmaceutical Inc.